This Pharma Company Stays Innovative by Doing Two Things
Harvard Business Review
MARCH 14, 2017
Roivant was addressing some sobering realities: In 2016, only 22 new drugs were approved by the U.S. While virtually all pharma companies say they encourage risk, in reality the failure of individual drug-development programs frequently results in career damage or even job loss for the research teams involved.
Let's personalize your content